Novartis Acquires Avidity Biosciences
Novartis has entered a $12 billion definitive merger agreement to acquire Avidity Biosciences, enhancing its RNA therapeutics pipeline.
The acquisition targets rare neuromuscular diseases with innovative therapies. Following the separation of Avidity's early-stage precision cardiology programs into a new publicly traded company, SpinCo.
Avidity's pioneering AOC platform for RNA therapeutics and its late-stage assets bolster our commitment to delivering innovative, targeted and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases - Vas Narasimhan, CEO of Novartis.
Novartis looks forward to developing Avidity's programs to change the trajectory of diseases for patients.
Author's summary: Novartis acquires Avidity Biosciences for $12 billion.
More News
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- #EyeOnMelissa: Uptick in ‘people in need’ seeking food in Negril ahead of Hurricane Melissa - Jamaica Observer
- #EyeOnMelissa: Holness says security forces deployed to deal with law and order - Jamaica Observer
- Dear ASEAN Leaders: Trumpism Is Not A Temporary Phenomenon. Here’s Why?
- Monday Morning Watch | Week of Oct. 27, 2025 - BirminghamWatch
- Squatters, renters and adult children bringing down The Villages - Villages-News.com
- Feeling like a dog chasing his own tail in a country and a society out of control
- #EyeOnMelissa: Hurricane Melissa forecast to make landfall within 24 hours - Jamaica Observer
- Mountain View council member talks climate policy with Saint Francis students